Screener
Ultragenyx Pharmaceutical RARE Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued liabilities | 221 | 265 |
| Liabilities for sales of future royalties | 76 | 69 |
| Other liabilities | 15 | 19 |
| Total current liabilities | 351 | 384 |
| Deferred tax liabilities | 30 | 30 |
| Liabilities for sales of future royalties | 1,126 | 1,147 |
| Other liabilities | 41 | 44 |
| Total liabilities | 1,548 | 1,605 |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's total current liabilities?
- Ultragenyx Pharmaceutical (RARE) reported total current liabilities of $351M in Q2 2026.
- How has Ultragenyx Pharmaceutical's total current liabilities changed year-over-year?
- Ultragenyx Pharmaceutical's total current liabilities increased by 19.7% year-over-year, from $293.24M to $351M.
- What is the long-term trend for Ultragenyx Pharmaceutical's total current liabilities?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's total current liabilities has grown at a 15.2% compound annual growth rate (CAGR), from $189.61M to $384M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Ultragenyx Pharmaceutical's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude